Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond

Chairpeople:

Martin Dreyling,¹ Gilles Salles²

Speakers:

Paolo Corradini,³ Jehan Dupuis,⁴ Steven Le Gouill,⁵ Marek Trněný⁶

1. Hospital of the Ludwig Maximilians University, Munich, Germany
2. Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Lyon, France
3. IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy
4. Centre Hospitalier Universitaire Henri Mondor, Créteil, France
5. Centre Hospitalier Universitaire de Nantes, Nantes, France
6. Charles University and General University Hospital, Prague, Czech Republic

Disclosure:

All the authors have been advisers and/or speakers for Celgene. Martin Dreyling has received research and grant support from Celgene, Janssen, Mundipharma, Pfizer, and Roche as well as honoraria and consultancy fees from these companies. He has also received honoraria and consultancy fees from Gilead and has participated in advisory boards for Bayer, Celgene, Gilead, and Janssen. Paolo Corradini has received honoraria and consultancy fees from Sanofi, Celgene, Novartis, Takeda, Janssen, and Servier, and has participated in advisory boards for Celgene, Novartis, and Sanofi. Jehan Dupuis has received honoraria and consultancy fees from Celgene. Steven Le Gouill has received research and grant support from Roche and Janssen, honoraria and consultancy fees from Celgene, Janssen, Roche, Mundipharma, and Gilead, and has participated in advisory boards for Roche, Janssen, Gilead, and Celgene. Marek Trněný has received research and grant support from Roche and Celgene, honoraria and consultancy fees from Roche, Celgene, Gilead, and Janssen, and has participated in advisory boards for Roche and Celgene. Gilles Salles has declared no relevant disclosures.

Acknowledgements:

Writing assistance was provided by Dr Juliet Bell of apothecom scopemedical Ltd.

Support:

The symposium and medical writing assistance was funded by Celgene. The views and opinions expressed are those of the authors as expressed during the symposium and not necessarily of Celgene.

Citation:

EMJ Hema. 2015;3[1]:54-64. DOI/10.33590/emjhematol/10312591. https://doi.org/10.33590/emjhematol/10312591.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.